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Vpr, one of the accessory gene products of HIV-1, is a 96-residue protein with several functions. It is involved in import of
the HIV-1 preintegration complex into the nucleus of nondividing cells, in cellular differentiation, inducing cell cycle arrest at
the G2/M phase, in immune suppression, and in enhancement of replication of the virus. We found recently that Vpr interferes
with the proliferation of mouse NIH3T3 fibroblasts but fails to arrest these cells in the G2 phase. Thus, it seems possible that
Vpr might retard cell proliferation via a novel pathway that is distinct from G2 arrest. To elucidate the mechanism by which
Vpr induces the retardation of cell growth, we developed a panel of expression vectors that encoded Vpr molecules with
deletions of specific putative domains, namely, the first a-helical domain, the second a-helical domain, a leucine zipper-like
domain, and an arginine-rich carboxy-terminal domain. These vectors were introduced into HeLa cells since expression of
Vpr can induce G2 arrest in such cells. A carboxy-terminally truncated form of Vpr, C81, which failed to induce G2 arrest, led
to the G1 arrest and retained the ability to prevent cell proliferation. All the other mutant proteins had completely lost the
capacity to induce G2 arrest and to suppress growth. Substitutions of Ile/Leu for Pro at positions 60, 67, 74, and 81 within the
leucine zipper-like domain of Vpr or of C81 revealed that Ile60, Leu67, and Ile74 play an important role in the C81-induced
suppression of growth, while Ile74 and Ile81 were found to be indispensable for Vpr-induced G2 arrest. Collectively, our
results strongly suggest that Vpr can retard cell proliferation independently of G2 arrest of the cell cycle. © 1999 Academic Press
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aINTRODUCTION
The genome of human immunodeficiency virus type 1
HIV-1) contains not only structural genes, such as gag,
ol, and env, but also the accessory genes vif, vpr, vpu,
nd nef. One such gene, vpr, encodes a 15-kDa nuclear
rotein of 96 amino acids that is incorporated into virions
hrough interaction with the p6 C-terminal product of Gag
Cohen et al., 1990; Kondo and Gottlinger, 1996; Kondo et
l., 1995; Lu et al., 1993). Vpr and matrix antigen (MA) act
irectly to promote the nuclear import of the HIV-1 pre-
ntegration complex via the karyopherin pathway (Gallay
t al., 1996; Popov et al., 1998), thereby allowing replica-
ion in nonproliferation targets, such as terminally differ-
ntiated macrophages (Heinzinger et al., 1994; Vodicka
t al., 1998). Vpr arrests the cell cycle at the G2/M phase
y preventing the activation of the p34cdc2-cyclin B com-
lex, and this inhibition appears to result from increased
hosphorylation of p34cdc2 at specific sites (Bartz et al.,
996; He et al., 1995; Jowett et al., 1995; Re et al., 1995;
ogel et al., 1995). The capacity for Vpr-mediated arrest
f the cell cycle is conserved among strongly divergent
imian immunodeficiency viruses (SIV) (Planelles et al.,
1 These two authors have contributed equally to this work.
2 To whom correspondence and reprint requests should be ad-sressed. Fax: 81 298 36 9050. E-mail: aida@rtc.riken.go.jp.
313996), suggesting an important role for Vpr in the life
ycle of such viruses. Indeed, the expression of the viral
enome is maximal during the G2 phase of the cell cycle,
nd Vpr increases the production of virus by delaying
ells at the point of the cell cycle where the long terminal
epeat (LTR) is most active (Felzien et al., 1998; Goh et al.,
998). In addition, Vpr causes the terminal differentiation
f certain types of cell (Levy et al., 1993) and the induc-
ion of apoptosis after cell cycle arrest (Stewart et al.,
997). Furthermore, there is evidence that Vpr seems to
e able to regulate apoptosis both positively and nega-
ively (Ayyavoo et al., 1997; Conti et al., 1998; Fukumori et
l., 1998). On the other hand, several cellular proteins
ave been reported to associate with Vpr, such as a
1-kDa cytosolic protein that forms a complex with the
lucocorticoid receptor protein (Refaeli et al., 1995; Zhao
t al., 1994), an unidentified 180-kDa protein (Refaeli et
l., 1995), Sp1 (Wang et al., 1995), TFIIB (Agostini et al.,
996), uracil DNA glycosylase (Bouhamdan et al., 1996),
HR23A (Withers-Ward et al., 1997), p53 (Sawaya et al.,
998), and a human 34-kDa mov34 homolog (Ma-
alingam et al., 1998). Thus, the various roles of Vpr
eem to involve modulation of the cellular environment
ia the interaction of Vpr with cellular partners.
A comparison of amino acid sequences and structural
nalysis reveal that a number of amino acid residues and
tructural motifs are conserved in the Vpr proteins of
0042-6822/99 $30.00
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314 NISHIZAWA ET AL.IV-1, HIV-2, and SIV lentiviruses (Tristem et al., 1992).
esidues 17–34 seem very likely to form an amphipathic
-helical domain (containing five acidic and four leucine
esidues), as predicted by the Chou-Fasman algorithm
Mahalingam et al., 1995a, 1995c). This domain appears
o be critical for expression and stability of Vpr, as well as
or incorporation into virions and nuclear localization
Mahalingam et al., 1995a, 1995c; Yao et al., 1995). A
egion spanning amino acids 46 through 74 is also pre-
icted to have a helical structure, although with a signif-
cantly lower hydrophobic moment (Mahalingam et al.,
995a), and it contains a determinant that is involved in
he translocation to the nucleus of the preintegration
omplex in nondividing cells (Nie et al., 1998). Another
nique domain lies within amino acids 60–81. This region
s rich in Ile/Leu residues and is known as the leucine
ipper-like domain (Mahalingam et al., 1997a; Wang et
l., 1996; Zhao et al., 1994). This structure is involved in
he nuclear localization of Vpr and in the specific inter-
ction with a host cellular protein that is important for the
unction of Vpr (Mahalingam et al., 1997a; Zhao et al.,
994). The carboxy-terminal 20-amino-acid arginine-rich
ail, which contains a cryptic nuclear localization signal
NLS), greatly impairs the nuclear localization of Vpr (Lu
t al., 1993; Mahalingam et al., 1997a; Yao et al., 1995;
hao et al., 1994; Zhou et al., 1998). Truncation of or
mino acid substitutions in this region result in failure to
nduce cell cycle arrest (Di Marzio et al., 1995; Ma-
alingam et al., 1997a; Zhou et al., 1998). Thus, it appears
hat the carboxy-terminal region of Vpr is also required
or induction of cell cycle arrest.
We found recently that Vpr interfered with the prolifer-
tion of mouse NIH3T3 fibroblasts but failed to induce
he G2 arrest of these same cells (Nishino et al., 1997).
ur findings suggested strongly that Vpr might retard cell
roliferation via a novel pathway that is distinct from G2
rrest. However, the mechanism for such retardation,
emained obscure. It was also unclear whether the same
henomenon might occur in other established cell lines,
n which the expression of Vpr can induce G2 arrest. To
xamine these issues, we chose HeLa cells as a model
ell line in which Vpr can induce G2 arrest. We identified
truncated form of Vpr, designated C81, that lacked the
arboxy-terminal arginine-rich region and failed to in-
uce G2 arrest in HeLa cells but retained the ability to
nterfere with the proliferation of these cells. Further-
ore, results with variants of C81 with mutations within
he leucine zipper-like domain, designed to disrupt the
eucine zipper structure, suggested that the pathway
tilized by Vpr for G2 arrest might be distinct from the
athway, whereby C81 retards cell proliferation without
2 arrest. Thus, we were able to demonstrate that Vpr
an interfere with cell growth by at least two different
echanisms, each of which involves a different pathway. aRESULTS
Construction of plasmids and expression of Vpr dele-
ion mutants. Vpr has a number of different functions
uring the life cycle of HIV-1, including nuclear import
nd the induction of cell cycle arrest at the G2 phase. The
arious biological activities of Vpr are correlated with
pecific structural features of the protein (Di Marzio et al.,
995; Mahalingam et al., 1997a, 1995a, 1995b, 1995c;
iller et al., 1996; Wang et al., 1996; Yao et al., 1995; Zhao
t al., 1994). As shown in Fig. 1A, Vpr can be divided into
our putative structural regions on the basis of its amino
cid sequence: (1) the first a-helical domain, extending
rom amino acids 17 to 34; (2) the second a-helical
omain, extending from amino acids 46 to 74; (3) the
eucine zipper-like domain, extending from amino acids
0 to 81; and (4) the arginine-rich carboxy-terminal do-
ain (Lu et al., 1993; Yao et al., 1995; Zhou et al., 1998).
n order to identify the region(s) involved in the ability of
pr to retard cell growth, we constructed cDNAs for Vpr
utants with deletion of each putative domain and then
ubcloned the cDNAs downstream of the SRa promoter
n the expression vector pME18Neo (Fig. 1A).
We examined the effects of the deletion of each puta-
ive domain by transiently transfecting HeLa cells with an
xpression vector that encoded wild-type or mutant Vpr,
onstructed by using the primers shown in Table 1. To
acilitate the assay, the wild-type and mutant proteins
ere given an amino terminal Flag tag with the se-
uence NH2-Met-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (Fig.
A). At 36 h after transfection, we examined the expres-
ion of Vpr by Western blotting analysis with MAb M2,
hich recognizes the Flag tag (Fig. 1C). We observed
ingle bands of proteins with apparent molecular
asses consistent with the predicted sequences in the
nalysis of HeLa cells that had been transfected with
ME18Neo that encoded wild-type Vpr, Vpr lacking 15
mino acids of the arginine-rich carboxy-terminal region
C81), Vpr with deletion of the first a-helical domain
D17–34), and amino-terminally truncated Vpr that lacked
7 or 35 amino acids (N17 and N35, respectively). The
74 mutant, with a deletion of 22 amino acids at the
arboxyl terminus, was expressed at levels significantly
ower than those of the wild-type Vpr. By contrast, no
pecific bands were detected in the analysis of HeLa
ells that had been transfected with pME18Neo that
ncoded a carboxy-terminally truncated Vpr that lacked
8 amino acids (C59), Vpr with deletion of the second
-helical domain or the leucine zipper-like domain
D46–74 and D60–81, respectively), or an amino-termi-
ally truncated Vpr that lacked 60 amino acids (N60), as
ell as the negative control vector pME18Neo-Flag. Ab-
ence of detectable mutant Vpr proteins was presumably
ue to the decreased stability of these proteins. In addi-
ion, all transfections of the four vector plasmids in
mounts up to 100 mg of transfected plasmid were neg-
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FFIG. 1. Construction and expression of mutant Vpr proteins. (A) Plasmids containing cDNA for the deleted mutant forms of Vpr were generated by
CR from HIV-1NL4-3. The positions of the predicted first a-helical domain, second a-helical domain, leucine zipper-like domain, and arginine-rich
arboxy-terminal domain are indicated. The regions of the Vpr generated by each construct are shown in black; grey showing represents the Flag-tag.
B) The mutations introduced within the leucine zipper-like domain of wild-type Vpr and C81. The sequences of the leucine zipper-like domain
represented by dark shaded) are shown in the single-letter amino acid code and the locations of four Ile/Leu residues are indicated. The sequences
f the mutant form of Vpr used in this study are indicated under the wild-type sequence, which was derived from HIV-1NL4-3. (C) Western blotting of
utant Vpr proteins. Cells were cotransfected with pME18Neo that encoded Flag-tagged wild-type Vpr (lanes 2 and 13), C59 (lane 3), C74 (lane 4),
81 (lane 5), D17–34 (lane 6), D46–74 (lane 7), D60–81 (lane 8), N17 (lane 9), N35 (lane 10), N60 (lane 11), I60P (lane 14), L67P (lane 15), I74P (lane
6), I81P (lane 17), C81 (lane 18), C81/I60P (lane 19), C81/L67P (lane 20), C81/I74P (lane 21), or C81/I81P (lane 22) or the control pME18Neo-Flag (lanes
and 12) together with the pSV-b-Galactosidase plasmid. Transfected cells were harvested 36 h after transfection. Same cells were subjected to an
ssay of b-galactosidase activity and the rest were lysed. Lysates with equal b-galactosidase activity were subjected to Western blotting with the
lag-specific MAb M2. Positions of the molecular mass markers are indicated.
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316 NISHIZAWA ET AL.tive (data not shown). Moreover, no specific bands were
etected when the analysis was performed with normal
ouse serum (data not shown). Thus, these results in-
icate that the putative second a-helical domain that
xtends from amino acids 46 to 74 might be involved in
xpression of Vpr. In subsequent experiments, we used
nly mutant forms of Vpr whose expression was detect-
ble by Western blotting analysis.
The C81 mutant protein retarded cell growth indepen-
ently of any induction of G2 arrest. To determine which
f the putative domains of Vpr is required for G2 arrest,
e cotransfected HeLa cells with pME18Neo that en-
oded wild-type, C74, C81, D17–34, N17, or N35 Vpr or the
ontrol pME18Neo-Flag together with a small amount of
GFP expression vector, pEGFP-N1, which served as a
arker plasmid. Forty-eight hours after transfection, we
tained the cells with propidium iodide and then deter-
ined the distribution within the cell cycle transfected
ells using a FACScan to measure the DNA content of
FP-expressing cells (Table 2 and Fig. 2). In the case of
ells transfected with the expression vector that en-
oded wild-type Vpr, there was a dramatic increase in
he proportion of cells in the G2/M phase of the cell cycle
s compared with cells transfected with the control vec-
or pME18Neo-Flag. By contrast, all transfections with
ectors that encoded our deletion mutants were unable
o arrest the cell cycle at the G2/M phase. However, one
f five mutants, C81 caused a block of the cell cycle at
he G1 phase; only 3.1% of the cells were in G2/M phase,
hile 76.7% of the cells were in G1.
To determine in further detail the effects of the deletion
n each putative domain in Vpr on cell proliferation, we
erformed a colony formation assay. HeLa cells were
ransfected with pME18Neo, which contains a neomycin-
esistance marker, that encoded wild-type and mutant
T
Oligonucleotide Primers
Mutant Forward primer
Restriction
endonuclea
pr 59-GAAGATATCCGAACAAGCCCCCAGAAGAC-39 EcoRV
59 59-GAAGATATCCGAACAAGCCCCCAGAAGAC-39 EcoRV
74 59-GAAGATATCCGAACAAGCCCCCAGAAGAC-39 EcoRV
81 59-GAAGATATCCGAACAAGCCCCCAGAAGAC-39 EcoRV
17–34 59-CCTAGGATATGGCTCCATAA-39
46–74 59-CGGCATAGCAGAATAGGCGTT-39 NaeI
60–81 59-GGAAGCCGGCGTTACTCGACAGAGGA-39 NaeI
17 59-CCGGATATCTGAATGGACACTAGAGCTTT-39 EcoRV
35 59-CCGGATATCTCCTAGGATATGGCTCCATA-39 EcoRV
60 59-CCGGATATCCATAATAAGAATTCTGCAAC-39 EcoRV
60P 59-GGAGTGGAAGCCCCAATTCGAATTCTGCAAC-39 NspV
67P 59-AAGAATTCTGCAGCAGCCACTGTTTATCCA-39 PstI
74P 59-GGGTGTCGACATAGCAGAATAGGAGT-39 SmaI
81P 59-TCGACATAGCAGGCCTGGCGTTACTCGA-39 AatI
81/I81P 59-GAAGATATCCGAACAAGCCCCCAGAAGAC-39 EcoRV
a The underlined sequences are restriction site of endonuclease.pr proteins and then, 48 h after transfection, transfectedells were transferred to selective medium that con-
ained G418. Twelve days later, surviving colonies were
ounted to assess the growth-inhibitory effects of the
arious proteins and the relative number of colonies was
alculated as the actual number of colonies/relative
-Gal activity to normalize the efficiency (Table 3). The
ercentage inhibition of the maximal proliferation in
eLa cells is also shown for each protein in Table 3.
ransfection of HeLa cells with pME18Neo-Fvpr resulted
n a dramatically reduced growth rate and prevented the
stablishment of drug-resistant cells, as compared with
ransfection with the control vector pME18Neo-Flag. This
esult suggested that Vpr can both induce the arrest of
eLa cells in the G2 phase and block cell growth. More-
ver, C81, which lacked the ability to induce G2 arrest and
eration of Vpr Mutantsa
Reverse primer
Restriction
endonuclease
9-GCTCTAGATTGGTACAAGCAGTTTTAGGC-39 XbaI
9-TCTCTAGATCAGGCTTCCACTCCTGCCCA-39 XbaI
9-GGGTCTAGATCAAATTCTGAAATGGATAAA-39 XbaI
9-GGTCTAGATCATATTCTGCTATGTCGACAC-39 XbaI
9-ATTGTATGGCTCCCTCTGTG-39
9-GCACCCATGTTGTCCTAAGTTATG-39 NaeI
9-ACTCCTGCCCACGTGTCCCCGTAAGTTTC-39 PmaCI
9-GCTCTAGATTGGTACAAGCAGTTTTAGGC-39 XbaI
9-GCTCTAGATTGGTACAAGCAGTTTTAGGC-39 XbaI
9-GCTCTAGATTGGTACAAGCAGTTTTAGGC-39 XbaI
9-TGCCCAAGTATCCCCGTAAG-39
9-TTATTATGGCTTCCACTCCTGCCCAAGTATCCCCGTAAG-39
9-GGGTCTGAAATGGATAAACAGCAG-39 SmaI
9-CACCCAATTCTGAAATGGAT-39
9-GGTCTAGATCAAGGCCTGCTATGTCGACAC-39 XbaI, AatI
XbaI AatI
TABLE 2
Cell Cycle Arrest Activity in HeLa Cells Expressing Wild-Type
and Deletion Mutant Vpr Proteinsa
Mutant Relative G2/M:G1 ratio G2 arrest
ontrol 0.29b 2c
ild type 1.00 1
74 0.29 2
81 0.04 2
17–34 0.38 2
17 0.36 2
35 0.33 2
a HeLa cells were transfected with pME18Neo that encodes Flag-
agged wild-type Vpr, mutant or control pME18Neo-Flag together with
he green fluorescent protein (GFP) expression vector, pEGFP-N1.
hen, 48 h after transfection, DNA content of cells was determined as
escribed in the legend of Fig. 2.
b Values were defined in each experiment by setting the G2/M:G1
atios for cells that expressed wild-type Vpr to 1.0. The results represent
he mean of three independent experiments of each mutant.ABLE 1
for Gen
se
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5c 1, Full G2 arrest; 2, no G2 arrest.
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317GROWTH SUPPRESSION BY C-TERMINALLY TRUNCATED Vpr OF HIV-1ained capacity to lead G1 arrest, retained the cell
rowth arrest activity, albeit to a lesser extent (approxi-
ately 65%) than wild-type Vpr. All the remaining mutants
ested that had failed to induce the G2 arrest also failed
o suppress the growth of HeLa cells.
FIG. 2. DNA content of HeLa cells that expressed Flag-tagged wild-
ME18Neo that encoded Flag-tagged wild-type, C74, C81, D17–34, N17
EGFP-N1. Then, 48 h after transfection, cells were harvested for an
FP-positive were analyzed by flow cytometry using the Lysis II for acqu
eaks of cells at the G1 and G2/M phases. The G2/M:G1 ratio is indica
TABLE 3
Proliferation of Colony Forming Cells Expressing Wild-Type
and Deletion Mutant Vpr Proteinsa
Mutant
Relative number of
coloniesb
Inhibition of growthc
(%)
ontrol 527.7 6 47.3d 0 6 10
pr 40.8 6 7.1 100 6 1
74 544.0 6 19.9 23 6 4
81 358.7 6 6.0 35 6 1
17–34 624.6 6 37.0 220 6 8
17 738.4 6 39.6 244 6 8
35 691.7 6 83.6 234 6 17
a HeLa cells were cotransfected with pME18Neo that encoded Flag-
agged wild-type Vpr, C74, C81, D17–34, N17 or N35 or the control
ME18Neo-Flag together with a pSV-b-Galactosidase plasmid. Then,
8 h after transfection, cells were harvested. Some cells were sub-
ected to an assay of b-galactosidase activity, and the rest were
eplated in selective medium that contained G418.
b The data shown present the relative number of drug-resistant
olonies counted twelve days after drug selection. The relative number
f colonies was calculated as actual number of colonies/relative b-Gal
ctivity.
c The blocking of colony formation by each mutant was normalized
y reference to parallel transfections with pME18Neo-Fvpr or a control
ME18Neo-Flag to 100 and 0% blocking, respectively.md Mean 6 SD.These results suggest that C81 mutant can retard cell
rowth via a mechanism different from that by which it
rrests cells at the G2 phase of the cell cycle. Thus, it
eems likely that Vpr protein has two functions in cell
rowth: it can suppress growth without G2 arrest of the
ell cycle and it can also induce G2 arrest. The former
ffect may correlate with a G1 arrest of cell cycle.
Mutagenesis of Ile/Leu residues in the leucine zipper-
ike domain in wild-type Vpr and C81. To determine
hether the Vpr-induced G2 arrest of the cell cycle and
he C81-induced suppression of growth without G2 arrest
re regulated by an independent pathway or the same
athway, we focused on the leucine zipper-like domain
rom amino acids 60 to 81 of Vpr. This region appears to
e able to form a typical leucine zipper-like structure of
he type found in a variety of transcription factors, which
an provide a site for direct contact with other proteins
Wang et al., 1996). The amino acid sequences of this
egion of Vpr derived from various isolates of HIV-1,
IV-2, and SIV are compared (data not shown). Four
le/Leu residues at positions 60, 67, 74, and 81 are almost
ully conserved and they are arranged similarly in the
eucine zippers identified in the transcription factors from
0 laboratory isolates of HIV-1. However, the Ile/Leu
esidues at positions 67 and 74 but not at positions 60
nd 81 are replaced by other amino acids, such as Ala,
ly, Gln, and Ser, in isolates of HIV-2 and SIV. Thus,
onservation of the four Ile/Leu residues in the leucine
ipper-like domain is characteristic of HIV-1. Further-
r and deletion mutant forms of Vpr. HeLa cells were transfected with
r the control pME18Neo-Flag together with a GFP expression vector,
of DNA content and stained with propidium iodide. Cells that were
nd ModFit LT for quantitative analysis of DNA content. Arrows indicate
the upper right of each graph.type Vp
, N35, o
alysis
isition aore, the leucine zipper-like domain in Vpr might con-
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318 NISHIZAWA ET AL.ribute to the pathogenicity of HIV-1 since several groups
f investigators (Mahalingam et al., 1997a; Wang et al.,
996, 1995) have shown that a leucine zipper-like domain
ight be an important functional determinant of Vpr of
IV.
To compare the effects of substitutions within the
eucine zipper-like domain on the two growth-suppress-
ng activities of Vpr, we generated derivatives of
ME18Neo that encoded the mutant forms of wild-type
pr and C81 with replacement of each Ile/Leu residue by
ro to introduce changes in the leucine zipper-like do-
ain of wild-type (I60P, L67P, I74P, and I81P) and C81
C81/I60P, C81/L67P, C81/I74P, and C81/I81P) Vpr pro-
eins (Fig. 1B). Western blotting analysis with MAb M2
evealed that each protein with a site-specific mutation
as expressed at detectable levels in the corresponding
ransfected cells (Fig. 1C).
The C81 mutant exploits a novel pathway to retard cell
rowth that is independent of the pathway that leads to
2 arrest. We analyzed the results of transfections with
ur series of Vpr expression vectors to define the Ile/Leu
esidues that are required for G2 arrest, as shown sche-
atically in Fig. 1B. The DNA content of HeLa cells that
ad been transiently transfected with each derivative of
ME18Neo that encoded Vpr with a site-specific muta-
ion was analyzed by flow cytometry (Fig. 3A). After tran-
ient transfection with I74P and I81P expression vectors,
o HeLa cells were arrested at the G2 phase, whereas
bout 17.7 and 17.2% of cells transfected with I60P and
67P expression vectors, respectively, were arrested at
he G2 phase, as compared to cells that expressed wild-
ype Vpr. Likewise, colony formation assay indicated that
fter transfection of HeLa cells with I74P and I81P ex-
ression vectors, these cells did not show growth inhi-
ition in contrast to I60P and L67P expression vectors
Fig. 3B). These results clearly indicate that the leucine
ipper-like domain, and in particular the Ile residues at
ositions 74 and 81, were indispensable for induction of
ell cycle arrest at the G2 phase and subsequent growth
rrest (Table 4).
In order to evaluate the significance of the leucine
ipper-like domain in C81 in preventing cell proliferation,
e transiently transfected HeLa cells with pME18Neo
hat encoded wild-type Vpr, C81, and C81 with site-spe-
ific mutations (C81/I60P, C81/L67P, C81/I74P, and C81/
81P). After transfection and overnight incubation, the
ells were incubated with [3H]thymidine and incorpora-
ion of the radiolabel into the cells was measured (Fig. 4).
he suppression the cell growth of HeLa cells trans-
ected with the C81 expression vector was stronger than
hat of cells transfected with the wild-type Vpr expression
ector (incorporation of approximately 7 3 103 and 1.6 3
04 cpm of [3H]thymidine, respectively, in the case of C81
nd wild-type Vpr). All of the four site-specific mutations
ecreased the growth-suppressive activity of C81. In par-icular, substitutions at Ile60, Leu67, and Ile74 completely aliminated this activity. After substitution of Ile81 by Pro,
utated C81 retained approximately 40% of the activity of
81 itself. Furthermore, no recovery of the ability to
nduce G2 arrest was observed in the case of any of the
utant forms of C81 with site-specific mutations (data
ot shown). These results suggest that the leucine zip-
er-like domain might be essential not only for G2 arrest
ut also for the suppression of growth without G2 arrest
nd, moreover, that the Ile/Leu residues at positions 60,
7, and 74 might be important for the growth arrest
nduced by C81 (Table 4).
As summarized in Table 4, induction of G2 arrest by Vpr
nd the retardation of growth by C81 appeared to depend
n different residues in the leucine zipper-like domain of
pr. Thus, our observations strongly suggest that G2
FIG. 3. Analysis of the cell cycle and the proliferation of colony
ormation of HeLa cells expressing the substitution mutant Vpr pro-
eins. HeLa cells were transfected with pME18Neo encoding Flag-
agged wild-type Vpr, I60P, L67P, I74P, or I81P or the control pME18Neo-
lag together with a GFP expression vector, pEGFP-N1 (A), or a pSV-
-Galactosidase plasmid (B). (A) At 48 h posttransfection, DNA content
f the cells was determined by flow cytometry as described in the
egend of Fig. 2. G2/M:G1 ratios are indicated at the upper right of each
raph. (B) Twelve days later, surviving colonies were counted and then
he relative number of colonies was calculated as actual number of
olonies/relative b-Gal activity as described in Table 3. Each column
nd error bar represent the mean 6 SD of results from three samples.rrest induced by wild-type Vpr and the C81-induced
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319GROWTH SUPPRESSION BY C-TERMINALLY TRUNCATED Vpr OF HIV-1uppression of growth might involve different mecha-
isms or pathways.
DISCUSSION
In a previous study, we have found that Vpr interfered
ith the proliferation of mouse NIH3T3 cells but failed to
nduce the G2 arrest of these cells (Nishino et al., 1997).
his finding suggested strongly that Vpr might be able to
etard cell proliferation via a pathway distinct from the
athway that leads to G2 arrest. In this study, we con-
irmed that the phenomenon observed in NIH3T3 cells
ccurred in another established cell line, in which the
xpression of Vpr can induce G2 arrest. Using C81, which
acked the carboxy-terminal arginine-rich region of Vpr,
nd HeLa cells, in which Vpr induces G2 arrest, we
btained evidence that Vpr can interfere with cell growth
ia two distinct pathways in the same cells, namely,
rowth suppression without G2 arrest and growth sup-
ression with G2 arrest are as follows: (i) Vpr induce G2
rrest and blocked the growth of HeLa cells. Flow cyto-
etric analysis indicated that C81 completely failed to
nduce G2 arrest in HeLa cells, even though the results of
he colony formation assay and the incorporation of
3H]thymidine showed that C81 inhibited the proliferation
f these same cells; and (ii) mutation analysis indicated
hat the induction of G2 arrest depended particularly on
he Ile residues at positions 74 and 81 in the putative
eucine zipper-like domain, whereas the suppression of
81 of cell proliferation without G2 arrest involved Ile/Leu
esidues at positions 60, 67, and 74. Our data indicated
learly that the functional residues required for the two
ifferent activities were different from one another. Col-
TABLE 4
Effects of Substitution of Ile/Leu Residues within the Leucine
ipper-like Domain of Wild-Type Vpr and C81 on the Activities of
hese Proteins
Activitya
G2 arrest
Suppression of growth,
independent of G2 arrest
ild-type Vpr 111 Unknownb
ubstitution at position 60 1 Unknown
67 1 Unknown
74 2 2
81 2 2
81 2 111
ubstitution at position 60 2 2
67 2 2
74 2 2
81 2 11
a Extent of activity: 2, none; 1, slight; 11, moderate; 111, marked.
b Whether the expression of Vpr and mutants retard the cell prolifer-
tion independently of G2 arrest is unknown.ectively, our results demonstrate that induction of G2 srrest and growth suppression without G2 arrest are
ndependent functions of Vpr. Indeed, our present result
uggests that C81-induced suppression of growth may
esult in G1 arrest. Therefore, it appears that C81 is an
mportant tool for characterization of the mechanism of
rowth suppression by Vpr without G2 arrest, and, in
ddition, C81 appears to provide the optimal protein
onformation for this function of Vpr.
Rogel et al. (1995) indicated that HIV-1 virions that
ontain an intact vpr gene are unable to establish the
hronic infection of T-cells. Furthermore, transfection of a
pr gene together with the neomycin-resistance gene in
he absence of other viral genes was found to decrease
he formation of geneticin-resistant colonies for 10 to 15
ays posttransfection (Planelles et al., 1995). It has been
hown recently that expression of Vpr in several lines of
uman tumor cells after transfection results in a marked
eduction in colony formation in vitro and a significantly
educed ability to form tumors in vivo (Mahalingam et al.,
997b). These results support the results of our colony
ormation assay, namely, that transfection of HeLa cells
ith a wild-type Vpr expression vector resulted in cells
ith a dramatically reduced growth rate and prevented
he establishment of the drug-resistant cells for 12 days
osttransfection. Thus, our data and those of others
ndicate that Vpr might act to prevent cell proliferation
ver a relatively long period. We demonstrated that G2
rrest is not required for C81-induced suppression of
rowth. Likewise, our previous report showed that Vpr
etards the growth of NIH3T3 cells independently of the
FIG. 4. Uptake of [3H]thymidine by HeLa cells that expressed sub-
titution mutant Vpr with site-specific. HeLa cells were transfected with
ME18Neo that encoded Flag-tagged wild-type Vpr, C81, C81/I60P,
81/L67P, C81/I74P, or C81/I81P or the control pME18Neo-Flag together
ith a pSV-b-Galactosidase plasmid. Twelve hours after transfection,
ome cells were assayed for b-Gal activity and the rest were replated
t 1 3 105 cells/well in 24-well flat-bottomed plates. After a 30-h
ncubation, cells were incubated for 12 h with 0.5 mCi of [3H]thymidine
nd then harvested on glass fiber filters. The incorporation of radioac-
ivity was determined by liquid scintillation counting and incorporation
f [3H]thymidine was calculated as radioactivity/b-Gal activity. Each
olumn and error bar represent the mean 6 SD of results from four
amples in two independent experiments.
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320 NISHIZAWA ET AL.nduction of G2 arrest (Nishino et al., 1997). These results
trongly suggest that wild-type Vpr might function to
lock cell proliferation without the induction of G2 arrest,
s does the C81 mutant protein. However, as in the case
f C81, it remains unclear whether the expression of
ild-type Vpr in cells leads to the suppression of cell
rowth independently of G2 arrest. One hypothesis sug-
ested by our results is that the expression of Vpr at high
evels in cells immediately and strongly induces G2 ar-
est and the induction of G2 arrest overcomes other
unctions of Vpr. It is now essential to elucidate the
echanism of the growth-suppressive activity of C81 that
oes not involve the induction of G2 arrest.
In the present study, we generated mutant forms of Vpr
ith deletion of each putative structural region, namely,
he first a-helical domain, the second a-helical domain,
he leucine zipper-like domain, and the arginine-rich car-
oxy-terminal domain. All of the mutant proteins failed to
nduce G2 arrest. There are two possible explanations for
hese results. First, failure to induce G2 arrest might have
een due to altered structural conformations associated
ith the mutated Vpr proteins. Alternatively, each of the
utative domains might play a pivotal role in induction of
2 arrest. The hypothesis that the entire domain struc-
ure of Vpr is required for induction of G2 arrest is sup-
orted by the following results. (i) In this study, proteins
ith site-specific mutations within the leucine zipper-like
omain of Vpr, I74P, and I81P failed to induce G2 arrest.
ii) Mahalingam et al. (1997a) reported that proteins with
wo missense mutations, A30L in the first a-helical do-
ain and R80A in the carboxy-terminal domain, failed to
nduce G2 arrest (Di Marzio et al., 1995). (iii) Vpr from
XB2 (with an 18-amino-acid deletion at carboxyl termi-
us) induced neither cell cycle arrest nor an unusual
orphological phenotype (Mahalingam et al., 1997a).
Recently, it was reported that activation by Vpr of
ranscription of HIV-1 is correlated with the ability of Vpr
o induce G2 arrest (Felzien et al., 1998; Goh et al., 1998).
n particular, Vpr was found to increase the production of
irus by delaying cells at the point in the cell cycle at
hich the viral LTR is most active (Goh et al., 1998).
oreover, stable expression of low levels of Vpr in host
ells appears to act as a negative regulator of apoptosis
n a line of human lymphoblastoid cells and represents
n additional strategy for the persistence and spread of
IV (Conti et al., 1998). Therefore, further study is re-
uired to define clearly whether the C81-induced sup-
ression of cell growth without G2 arrest regulated the
eplication of HIV-1.
MATERIALS AND METHODS
The construction of plasmids. HIV-1NL4-3 (Adachi et al.,
986) vpr was amplified by PCR with primers indicated in
able 1 and it was subcloned between the XbaI and
1coRV sites of pBluescript II (SK ) (Stratagene, La Jolla, fA) that encoded a Flag with the following amino acid
equence: NH2-Met-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys,
o yield a pSK-Fvpr. The XhoI–NotI fragment containing
pr and the Flag sequence of pSK-Fvpr was further sub-
loned downstream of the SRa promoter in the expres-
ion vector pME18Neo (Tajima et al., 1998) to yield a
lasmid designated pME18Neo-Fvpr (Nishino et al.,
997). In addition, pME18Neo-Flag, which contained only
he Flag sequence, was constructed as a control vector
Nishino et al., 1997). The vpr sequences with deletions,
hich encoded proteins designated C59, C74, C81, N17,
35, and N60, together with an amino-terminal Flag
equence, were amplified by PCR with pSK-Fvpr as tem-
late and the primers shown in Table 1. Each XhoI–NotI
ragment containing a deleted vpr sequence plus the
lag-encoded sequence was then subcloned into
ME18Neo. To generate the substitution mutants desig-
ated, I60P, L67P, I74P, and I81P, we introduced site-
pecific mutations into pSK-Fvpr by following the instruc-
ions in the manual provided with the ExSite PCR-based
ite-directed mutagenesis kit from Stratagene (Weiner et
l., 1994), as shown schematically in Fig. 1B. Leu or Ile
odons in the leucine zipper-like domain were changed
o Pro codons by long and accurate PCR (LA-PCR) with
SK-Fvpr as the template and the primers indicated in
able 1. The primers were designed to introduce the
esired amino acids of specific sites, as well as specific
ite of restriction enzyme (Table 1). Each XhoI–NotI frag-
ent, including the site-mutated vpr and Flag se-
uences, in pSK-Fvpr was excised and subcloned into
ME18Neo. Similarly, cDNAs for D17–34, D46–74, and
60–81 were amplified by LA-PCR with pSK-Fvpr as
emplate and the primers indicated in Table 1, and each
he XhoI–NotI fragment was then subcloned into
ME18Neo. To generate three substitution mutants of
81, namely, C81/I60P, C81/L67P, and C81/I74P, we ex-
ised the EcoRV–SalI fragment that encoded from amino
cids 1 to 75 of the Vpr protein from pSK-FI60P, pSK-
L67P, or pSK-FI74P, which corresponded to site-specific
utations in pSK-Fvpr. We introduced each fragment into
SK-FC81, and then each XhoI–NotI fragment that in-
luded the mutated vpr and Flag sequences was intro-
uced into pME18Neo. To generate the C81/I81P mutant,
he product of PCR was amplified by LA-PCR with pSK-
I81P as template and the primers indicated in Table 1.
he product was subcloned between the EcoRV and
baI sites of pSK-Fvpr, and then the XhoI–NotI fragment
hat included the mutated vpr and Flag sequence was
xcised and subcloned into pME18Neo. All constructs
escribed above were verified by nucleotide sequencing
y the dideoxy chain-termination method (Sanger et al.,
977) with a BcaBEST dideoxy sequencing kit (Takara,
tsu, Japan).
pEGFP-N1 encodes a red-shifted variant of wild-type
reen fluorescent protein (GFP), which has been modi-
ied for brighter fluorescence (Cormack et al., 1996). It
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321GROWTH SUPPRESSION BY C-TERMINALLY TRUNCATED Vpr OF HIV-1as used for flow cytometry. pSV-b-Galactosidase en-
odes a bacterial b-galactosidase and was used for
ormalization of the efficiency of transfection.
Cell culture and transfection. Human cervical HeLa
ells were maintained in RPMI 1640 medium supple-
ented with 10% heat-inactive fetal calf serum (FCS),
enicillin (100 U/ml), and streptomycin (100 mg/ml). Cells
1 3 107) were transfected with 47.5 mg of expression
ector and 2.5 mg of pSV-b-Galactosidase or 2.5 mg of
EGFP-N1 by electroporation in a 0.4-cm-diameter cu-
ette using a Bio-Rad gene pulsar (Richimond, CA) at 300
and 975 mF.
Western blotting. Thirty-six hours after transfection, the
xpression of Vpr was examined by Western blotting
nalysis as described previously (Tajima et al., 1998).
Analysis of the cell cycle. Forty-eight hours after trans-
ection, cells were harvested, fixed in 1% formaldehyde
nd 70% ethanol, and then incubated in phosphate-buff-
red saline that contained propidium iodide (50 mg/ml),
Nase A (50 mg/ml), and FCS (2%, v/v) for 60 min at room
emperature. The fluorescence of 10,000 cells was ana-
yzed on a FACScan system (Becton-Dickinson, Moun-
ain View, CA) using the Lysis II software (Becton-Dick-
nson). Data are presented after gating to eliminate cells
n which GFP emitted strong fluorescence. Ratios of
umbers of cells in the G1 and G2/M phase (G2/M:G1
atios) were calculated with ModFit LT software (Verity
oftware House, Topsham, ME).
Proliferation of colony-forming cells. Forty-eight hours
fter transfection, cells were harvested and divided into
wo portions. Some cells were subjected to an assay of
-Gal activity (b-Gal Reporter Gene Assay kit; Boeh-
inger-Mannheim, Mannheim, Germany), and the rest
ere replated (5 3 105) in a 10-cm-diameter dish with 10
l of growth medium that contained 1 mg/ml of G418
Gibco BRL, Grand Island, NY). After 12 days, the G418-
esistant colonies were fixed in methanol, stained with
iemsa solution, and counted. To normalize the effi-
iency of transfection, the number of colonies was cal-
ulated relative to the initial b-Gal activity.
Incorporation of [3H]thymidine. Twelve hours after
ransfection, cells were replated at 1 3 105 cells/well in
4-well flat-bottomed plates. Then 30 h later, 0.5 mCi of
3H]thymidine (NEN) was added to each well and incu-
ation was continued for 8 h. The cells were harvested
nd collected on a glass fiber filter and the radioactivity,
s counts per minutes, was determined by liquid scintil-
ation counting. To normalize the efficiency of transfec-
ion, relative incorporation of [3H]thymidine was calcu-
ated as radioactivity/b-Gal activity.
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